Clinical trial
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
NCT00214110 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00214110 |
|---|---|
| Title | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] |
| Official title | Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS] |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) |
| Intervention type | Drug |
| Interventions | Tamoxifen |
| Enrollment | 100 |
| Start date | Jan 1, 2001 |
| Completion | Jan 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: